Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 12/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4679167 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM5CHRM1MAPK14CXCR3 | |
| SCHEMBL4680034 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM5CHRM1MAPK14CXCR3 | |
| Hydrochloric Acid SCHEMBL4678178 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM5CHRM1MAPK14CXCR3 | |
| Hydrochloric Acid SCHEMBL4678173 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM5CHRM1MAPK14CXCR3 | |
| Phosphoric Acid SCHEMBL4678958 | 0.96 | CYP2D6 (0.91) | CYP2D6CHRM5CHRM1MAPK14CXCR3 | |
| SCHEMBL27501473 | 0.94 | CYP2D6 (0.90) | CYP2D6CHRM5CHRM1MAPK14CXCR3 | |
| Hydrochloric Acid SCHEMBL4685873 | 0.94 | CYP2D6 (0.88) | CYP2D6CHRM5CHRM1MAPK14CXCR3 | |
| Hydrochloric Acid SCHEMBL4680063 | 0.93 | CYP2D6 (0.88) | CYP2D6CHRM5CHRM1MAPK14CXCR3 | |
| SCHEMBL4678837 | 0.93 | CYP2D6 (0.86) | CYP2D6CHRM5CHRM1MAPK14CXCR3 | |
| SCHEMBL4679094 | 0.93 | CYP2D6 (0.86) | CYP2D6CHRM5CHRM1MAPK14CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1058680-B1 | 2-ARYLETHYL-(PIPERIDIN-4-YLMETHYL)AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | claimed |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | claimed |
| EP-1567149-A2 | PHARMACEUTICAL COMPOSITION COMPRISING BETA-3-ADRENOCEPTOR AGONISTS AND ANTIMUSCARINIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-31 | — | — | EP | claimed |
| WO-2004047838-A2 | PHARMACEUTICAL COMPOSITION COMPRISING BETA-3-ADRENOCEPTOR AGONISTS AND ANTIMUSCARINIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-06-10 | — | — | WO | claimed |
| US-6319920-B1 | MUSCARINIC RECEPTOR ANTAGONIST USED IN GASTROINTESTINAL, GENITOURINARY TRACT, RESPIRATORY TRACT, CARDIOVASCULAR SYSTEM, CENTRAL NERVOUS SYSTEM DISORDERS AND IN ANESTHESIOLOGY AND OPHTHALMOLOGY | SYNTEX (U.S.A.) LLC | 2001-11-20 | — | — | US | claimed |
| EP-1058680-B1 | 2-ARYLETHYL-(PIPERIDIN-4-YLMETHYL)AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| EP-1769792-A1 | Use of a beta-3 adrenoceptor agonist for the treatment of renal and bladder problems | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | US | disclosed |
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1567149-A2 | PHARMACEUTICAL COMPOSITION COMPRISING BETA-3-ADRENOCEPTOR AGONISTS AND ANTIMUSCARINIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004047838-A2 | PHARMACEUTICAL COMPOSITION COMPRISING BETA-3-ADRENOCEPTOR AGONISTS AND ANTIMUSCARINIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-06-10 | — | — | WO | disclosed |
| US-6319920-B1 | MUSCARINIC RECEPTOR ANTAGONIST USED IN GASTROINTESTINAL, GENITOURINARY TRACT, RESPIRATORY TRACT, CARDIOVASCULAR SYSTEM, CENTRAL NERVOUS SYSTEM DISORDERS AND IN ANESTHESIOLOGY AND OPHTHALMOLOGY | SYNTEX (U.S.A.) LLC | 2001-11-20 | — | — | US | disclosed |
| EP-1058680-A1 | 2-ARYLETHYL-(PIPERIDIN-4-YLMETHYL)AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999043657-A1 | 2-ARYLETHYL-(PIPERIDIN-4-YLMETHYL)AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261328-A1 | Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents | ADRB3, ADRB2, ADRB1 | CYP2D6 666/4885CHRM5 22/4885CHRM1 33/4885 |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | ADRB3, ADRB2, ADRB1 | CYP2D6 1732/4885CHRM5 105/4885CHRM1 199/4885 |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | ADRB3, ADRB2, ADRB1 | CYP2D6 4009/4885CHRM5 49/4885CHRM1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.